NASDAQ:CLRB - Cellectar Biosciences Stock Price, Forecast & News

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences shares reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences Inc (NASDAQ:CLRB) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.04. View Cellectar Biosciences' Earnings History.

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cellectar Biosciences.

3 brokers have issued 1 year price targets for Cellectar Biosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Cellectar Biosciences' stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 99.8% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

News articles about CLRB stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectar Biosciences earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cellectar Biosciences.

Cellectar Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 311,900 shares, an increase of 88.9% from the January 15th total of 165,100 shares. Based on an average daily trading volume, of 123,600 shares, the short-interest ratio is currently 2.5 days. Approximately 3.4% of the company's shares are sold short. View Cellectar Biosciences' Current Options Chain.

Some companies that are related to Cellectar Biosciences include CymaBay Therapeutics (CBAY), ESSA Pharma (EPIX), Cyclerion Therapeutics (CYCN), Aquestive Therapeutics (AQST), REDHILL BIOPHAR/S (RDHL), Xeris Pharmaceuticals (XERS), Millendo Therapeutics (MLND), Zynerba Pharmaceuticals (ZYNE), IMMUTEP LTD/S (IMMP), Trillium Therapeutics (TRIL), Northwest Biotherapeutics (NWBO), Chimerix (CMRX), Savara (SVRA), Axovant Gene Therapies (AXGT) and CV Sciences (CVSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.12%) and Game Plan Financial Advisors LLC (0.46%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

CLRB stock was bought by a variety of institutional investors in the last quarter, including Game Plan Financial Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLRB stock can currently be purchased for approximately $3.17.

Cellectar Biosciences has a market capitalization of $29.79 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

The official website for Cellectar Biosciences is http://www.cellectar.com/.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]